AL

Angelini Lumira Biosciences Fund

North America, Maryland, United States, Rockville

Description

Angelini Lumira Biosciences Fund is a corporate venture capital fund established by Angelini Pharma.

Investor Profile

Angelini Lumira Biosciences Fund has made 2 investments, with 0 in the past 12 months and 100% as lead.

Stage Focus

  • Seed (50%)
  • Series B (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Health Care
  • Biotechnology
  • Medical
  • Neuroscience
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Angelini Lumira Biosciences Fund frequently co-invest with?

Angelini Ventures
Europe, Lazio, Italy, Rome
Co-Investments: 1
UL
North America, Virginia, United States, Charlottesville
Co-Investments: 1
3B Future Health Fund
Europe, Bayern, Germany, Monaco
Co-Investments: 1
LivaNova
Europe, England, United Kingdom, London
Co-Investments: 1
Mayo Clinic
North America, Minnesota, United States, Rochester
Co-Investments: 1
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Virginia Innovation Partnership Corporation
North America, Virginia, United States, Richmond
Co-Investments: 1
PV
North America, Georgia, United States, Loganville
Co-Investments: 1
KC
North America, Virginia, United States, Reston
Co-Investments: 1
Jazz Venture Partners
North America, California, United States, San Francisco
Co-Investments: 1

What are some of recent deals done by Angelini Lumira Biosciences Fund?

Cadence Neuroscience

Redmond, Washington, United States

Cadence Neuroscience is an early-stage company developing medical device therapies for epilepsy.

Health CareNeuroscienceTherapeutics
Series BFeb 28, 2023
Amount Raised: $26,029,994
GenEp

Charlottesville, Virginia, United States

GenEp is a pre-clinical stage biotechnology company based on intellectual property assets.

BiotechnologyHealth CareMedical
SeedOct 26, 2021
Amount Raised: $1,450,000